| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply...
-SEC Filing
B of A Securities analyst Jason Gerberry maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and raises the price target...
FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2...
Needham analyst Serge Belanger upgrades Amphastar Pharma (NASDAQ:AMPH) from Hold to Buy and announces $36 price target.
According to IQVIA, the U.S. sales for Venofer® were approximately $513 million for the 12 months ended June 30, 2025. Pipeline...
Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target fro...
Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.7...
